| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Erlotinib Hydrochloride | FAERS: 4 | US FAERS | |
| 2 | Bosentan | FAERS: 1 | US FAERS | |
| 3 | Dabigatran | FAERS: 1 | US FAERS | |
| 4 | Exenatide | FAERS: 1 | US FAERS | |
| 5 | Imatinib Mesylate | FAERS: 1 | US FAERS | |
| 6 | Irinotecan | FAERS: 1 | US FAERS | |
| 7 | Lenalidomide | FAERS: 1 | US FAERS | |
| 8 | Thalidomide | FAERS: 1 | US FAERS | |
| 9 | Topotecan | FAERS: 1 | US FAERS | |
| 10 | Zoledronic Acid | FAERS: 1 | US FAERS | |
| 11 | fluticasone furoate | FAERS: 1 | US FAERS | |
| 12 | Aminophylline | OFFSIDES | ||
| 13 | Etoposide | OFFSIDES | ||
| 14 | Irinotecan | OFFSIDES | ||
| 15 | Moclobemide | OFFSIDES |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120240
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.